S100P/RAGE signaling regulates microRNA-155 expression via AP-1 activation in colon cancer

Experimental Cell Research

Volumn 319, Issue 13, 2013, Pages 2081-2090

  Onyeagucha, Benjamin Chidi ^a,b   Mercado Pimentel, Melania E ^b,c   Hutchison, Jennifer ^b   Flemington, Erik K ^d,e   Nelson, Mark A ^a,b,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d Louisiana Cancer Research Consortium   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AP 1; Colon cancer; MiR 155; MiR 155 sponge; RAGE; S100P

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; MICRORNA 155; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN C JUN; PROTEIN S 100; TRANSCRIPTION FACTOR AP 1;

ARTICLE; CANCER CELL; CELL INVASION; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84879880601     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.05.009     Document Type: Article

References (59)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2012, 62(1):10-29.
2. Sheth K.R., Clary B.M. Management of hepatic metastases from colorectal cancer. Clin. Colon. Rectal. Surg. 2005, 18(3):215-223.
3. Jemal A., et al. Cancer statistics. CA Cancer J. Clin. 2010, 60(5):277-300.
4. Elias D., et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann. Surg. Oncol. 2005, 12(11):900-909.
5. Gout S., Huot J. Role of cancer microenvironment in metastasis: focus on colon cancer. Cancer Microenviron. 2008, 1(1):69-83.
6. Tse J.C., Kalluri R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J. Cell. Biochem. 2007, 101(4):816-829.
7. Eccles S.A., Welch D.R. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007, 369(9574):1742-1757.
8. Becker T., et al. S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties. Eur. J. Biochem. 1992, 207(2):541-547.
9. Parkkila S., et al. The calcium-binding protein S100P in normal and malignant human tissues. BMC Clin. Pathol. 2008, 8:2.
10. Chandramouli A., et al. The induction of S100p expression by the Prostaglandin E(2) (PGE(2))/EP4 receptor signaling pathway in colon cancer cells. Cancer Biol. Ther. 2010, 10(10):1056-1066.
11. Arumugam T., Ramachandran V., Logsdon C.D. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J. Natl. Cancer Inst. 2006, 98(24):1806-1818.
12. Wang G., et al. Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res. 2006, 66(2):1199-1207.
13. Mousses S., et al. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res. 2002, 62(5):1256-1260.
14. Bulk E., et al. Adjuvant therapy with small hairpin RNA interference prevents non-small cell lung cancer metastasis development in mice. Cancer Res. 2008, 68(6):1896-1904.
15. Arumugam T., et al. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J. Biol. Chem. 2004, 279(7):5059-5065.
16. Barry S., et al. S100P is a metastasis-associated gene that facilitates transendothelial migration of pancreatic cancer cells. Clin. Exp. Metastas. 2012.
17. Fuentes M.K., et al. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis. Colon. Rectum. 2007, 50(8):1230-1240.
18. Arumugam T., et al. S100P promotes pancreatic cancer growth, survival, and invasion. Clin. Cancer Res. 2005, 11(15):5356-5364.
19. Ding Q., et al. APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J. Clin. Invest. 2011, 121(11):4526-4536.
20. Beer D.G., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 2002, 8(8):816-824.
21. Arumugam T., et al. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin. Cancer Res. 2012, 18(16):4356-4364.
22. Jiang L., et al. Targeting S100P inhibits colon cancer growth and metastasis by Lentivirus-mediated RNA interference and proteomic analysis. Mol. Med. 2011, 17(7-8):709-716.
23. Donato R. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr. Mol. Med. 2007, 7(8):711-724.
24. Volinia S., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Nat. Acad. Sci. U.S.A. 2006, 103(7):2257-2261.
25. Tili E., et al. Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc. Nat. Acad. Sci. U.S.A. 2011, 108(12):4908-4913.
26. Shibuya H., et al. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 2010, 79(3-4):313-320.
27. Eis P.S., et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc. Nat. Acad. Sci. U.S.A. 2005, 102(10):3627-3632.
28. Yin Q., et al. B-cell receptor activation induces BIC/miR-155 expression through a conserved AP-1 element. J. Biol. Chem. 2008, 283(5):2654-2662.
29. Kong W., et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol. Cell. Biol. 2008, 28(22):6773-6784.
30. Chang S., et al. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat. Med. 2011, 17(10):1275-1282.
31. Gatto G., et al. Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway. Nucleic Acids Res. 2008, 36(20):6608-6619.
32. Kutty R.K., et al. Inflammatory cytokines regulate microRNA-155 expression in human retinal pigment epithelial cells by activating JAK/STAT pathway. Biochem. Biophys. Res. Commun. 2010, 402(2):390-395.
33. Pu J., et al. Adrenaline promotes cell proliferation and increases chemoresistance in colon cancer HT29 cells through induction of miR-155. Biochem. Biophys. Res. Commun. 2012, 428(2):210-215.
34. Bianchi R., Giambanco I., Donato R. S100B/RAGE-dependent activation of microglia via NF-kappaB and AP-1 Co-regulation of COX-2 expression by S100B, IL-1beta and TNF-alpha. Neurobiol. Aging 2010, 31(4):665-677.
35. Hodgkinson C.P., Ye S. Toll-like receptors, their ligands, and atherosclerosis. Sci. World J. 2011, 11:437-453.
36. Tang C.H., Keng Y.T., Liu J.F. HMGB-1 induces cell motility and alpha5beta1 integrin expression in human chondrosarcoma cells. Cancer Lett. 2012, 322(1):98-106.
37. Chandramouli A., et al. MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers. Cancer Biol. Ther. 2012, 13(3):175-183.
38. Yin Q., et al. MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways. J. Virol. 2008, 82(11):5295-5306.
39. Liang H., et al. Knockdown of RAGE expression inhibits colorectal cancer cell invasion and suppresses angiogenesis in vitro and in vivo. Cancer Lett. 2011, 313(1):91-98.
40. He Y.Q., et al. Estradiol regulates miR-135b and mismatch repair gene expressions via estrogen receptor-beta in colorectal cells. Exp. Mol. Med. 2012, 44(12):723-732.
41. Verde P., et al. Deciphering AP-1 function in tumorigenesis: fra-ternizing on target promoters. Cell Cycle 2007, 6(21):2633-2639.
42. Domann F.E., et al. Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Cell Growth Differ. 1994, 5(1):9-16.
43. Thompson E.J., et al. A dominant negative c-jun specifically blocks okadaic acid-induced skin tumor promotion. Cancer Res. 2002, 62(11):3044-3047.
44. Suto R., et al. Dominant-negative mutant of c-Jun gene transfer: a novel therapeutic strategy for colorectal cancer. Gene Ther. 2004, 11(2):187-193.
45. Ebert M.S., Sharp P.A. MicroRNA sponges: progress and possibilities. RNA 2010, 16(11):2043-2050.
46. Kluiver J., et al. Generation of miRNA sponge constructs. Methods 2012, 58(2):113-117.
47. Brown B.D., Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat. Rev. Genet. 2009, 10(8):578-585.
48. Bakirtzi K., et al. Neurotensin signaling activates microRNAs-21 and -155 and Akt, promotes tumor growth in mice, and is increased in human colon tumors. Gastroenterology 2011, 141(5):1749-1761. e1.
49. Rehbein G., et al. Molecular regulation of S100P in human lung adenocarcinomas. Int. J. Mol. Med. 2008, 22(1):69-77.
50. Fukushima N., et al. Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays. Oncogene 2004, 23(56):9042-9051.
51. Russo J., et al. Cancer risk related to mammary gland structure and development. Microsc. Res. Tech. 2001, 52(2):204-223.
52. Amler L.C., et al. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res. 2000, 60(21):6134-6141.
53. Li S., et al. microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells. Mol. Med. Rep. 2012, 5(4):949-954.
54. Li C.L., et al. microRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis. Oncol. Rep. 2012, 27(6):1960-1966.
55. Mattiske S., et al. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol. Biomar. Prev. 2012, 21(8):1236-1243.
56. Han Z.B., et al. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J. Cancer Res. Clin. Oncol. 2012, 138(1):153-161.
57. Jiang S., et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010, 70(8):3119-3127.
58. Valeri N., et al. Modulation of mismatch repair and genomic stability by miR-155. Proc. Nat. Acad. Sci. U.S.A. 2010, 107(15):6982-6987.
59. Kim J.K., et al. Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma. Int. J. Oncol. 2009, 35(6):1257-1264.